Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with sequential chemotherapy and radiotherapy for first-line advanced esophageal cancer
ChiCTR2100052444Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in esophageal cancer, sponsored by Shandong Cancer Hospital. Primary endpoints: Progression-free survival and Toxic reaction. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2100052444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052444.